Servier moved to deepen its neurology strategy by acquiring Edgewise’s sevasemten and signaling continued M&A buildout across therapeutic franchises. The deal underscores how large pharma is using acquisitions to accelerate pipeline establishment where internal development timelines are stretched. The acquisition also reflects Servier’s focus on commercialization readiness, with the company signaling a potential next-year launch depending on development and regulatory progress. The move arrives as European peers continue consolidating assets to compete in high-demand neurology categories.